# XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

> **NCT07688577** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Xilio Development, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** XTX501

## Key facts

- **NCT ID:** NCT07688577
- **Lead sponsor:** Xilio Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-11
- **Final completion:** 2029-11
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688577, "XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*